<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771952</url>
  </required_header>
  <id_info>
    <org_study_id>14386</org_study_id>
    <nct_id>NCT01771952</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia</brief_title>
  <official_title>Prospective, Randomized, Double Blind Evaluation of the Efficacy of a Single Dose of Synvisc-One® (6.0 cc) for the Treatment of Patellofemoral Chondromalacia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how safe a knee injection called Synvisc-One® is in&#xD;
      patients with a condition called chondromalacia patella and how well in works in treating the&#xD;
      condition.&#xD;
&#xD;
      Chondromalacia patella is a common cause of kneecap pain or front knee pain. Often called&#xD;
      &quot;Runner's Knee,&quot; this condition often affects young, otherwise healthy individuals.&#xD;
&#xD;
      Chondromalacia is due to irritation of the undersurface of the kneecap. The undersurface of&#xD;
      the kneecap, or patella, is covered with a layer of smooth cartilage. This cartilage normally&#xD;
      glides effortlessly across the knee during bending of the joint. In some individuals, the&#xD;
      cartilage on the undersurface of the knee cap becomes irritated and soft, resulting in pain.&#xD;
      Potential treatments for this condition include rest, injections (numbing or&#xD;
      anti-inflammatory medications to reduce swelling and pain), and/or guided strengthening&#xD;
      exercises which may help reduce pain.&#xD;
&#xD;
      Other Treatments are being evaluated. This study is about Synvisc-One® an experimental device&#xD;
      that has been approved by the Food and Drug Administration (FDA) for the treatment of pain in&#xD;
      osteoarthritis (OA) of the knee in patients who have failed to respond to treatments that do&#xD;
      not involve drugs or surgery and simple pain medication such as acetaminophen. Synvisc-One®&#xD;
      is a gel-like substance that, when injected into a joint, acts to lubricate and cushion the&#xD;
      joint. Synvisc-One® is made from hyaluronan, which is a molecule that is found normally in&#xD;
      joint fluid.&#xD;
&#xD;
      Synvisc-One® has not been proven to be safe or helpful in patients with chondromalacia&#xD;
      patella (cartilage irritation or softening of the undersurface of the 'knee cap'). So far,&#xD;
      this drug/device has been given to over 10,000 people who have knee pain (due to&#xD;
      osteoarthritis) and has been proven safe and effective in patients with moderate to severe&#xD;
      pain due to knee joint osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:&#xD;
&#xD;
      Screening visit:&#xD;
&#xD;
      After written informed consent is obtained, initial screening will consist of a thorough&#xD;
      medical history and physical examination and standing, bilateral PA, lateral and merchant&#xD;
      view x-ray evaluation. Special attention will be given to inclusion and exclusion criteria as&#xD;
      listed above. Only patients who meet all inclusion and exclusion criteria will be allowed to&#xD;
      continue to Baseline outcomes data collection and randomization. The following subjective&#xD;
      outcomes, clinical examination and quadriceps strength data will be collected at each&#xD;
      session.&#xD;
&#xD;
      Subjective Outcomes&#xD;
&#xD;
        -  Knee Injury Outcome and Osteoarthritis Score (KOOS)&#xD;
&#xD;
        -  Anterior knee pain rating during single-leg squat (10cm visual analog scale-VAS)&#xD;
&#xD;
      Quadriceps strength testing&#xD;
&#xD;
      • Maximal, normalized isometric knee extension force (N/kg)&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Each subject will be randomly assigned in a 1:1 ratio to receive one of the treatments&#xD;
      (group) described above. Randomization will be done a priori via a random number generator.&#xD;
      Group assignments will be sealed in an envelope each containing a number from 001-100.&#xD;
      Randomization envelope #001 will be used for the first subject, #002 for the second and so&#xD;
      on.&#xD;
&#xD;
      Blinding:&#xD;
&#xD;
      Both examiner and patient will be blinded to treatment/ group assignment. During the&#xD;
      injection procedure, we will block patients' view of the injection with the use of a physical&#xD;
      screen (pillowcase, blanket, sheet, etc) in order to assure the patient is blinded to&#xD;
      treatment. Patients will be &quot;un-blinded&quot; after the final study endpoints have been collected&#xD;
      or if needed due to early withdraw or other medical emergency. To maintain blinding and avoid&#xD;
      measurement bias, the injecting physician will be different from the investigators performing&#xD;
      outcomes assessments.&#xD;
&#xD;
      Medication/ Treatment Restrictions and Monitoring:&#xD;
&#xD;
        -  Patients will be instructed to refrain from any other intra-articular treatment or&#xD;
           therapy while enrolled in this study&#xD;
&#xD;
        -  Patients will be interviewed regarding medication usage (dosage and frequency) at each&#xD;
           visit.&#xD;
&#xD;
        -  Patients will be instructed to refrain from using any medicine for pain with the&#xD;
           exception of OTC Tylenol.&#xD;
&#xD;
      Standardized Exercise prescription:&#xD;
&#xD;
      Patients will be prescribed a standardized home-based quadriceps strengthening program.&#xD;
      Patients will be educated on duration and frequency for exercises and will be provided an&#xD;
      exercise log that will provide exercise descriptions and reminders as well as a method for&#xD;
      exercise compliance. Subjects will return exercise books at each visit for compliance&#xD;
      recording.&#xD;
&#xD;
      Follow-up visits&#xD;
&#xD;
        -  1 month following injection: Patients will return at 4 weeks (approx 30±7 days)&#xD;
           following injection. The following outcomes will be recorded during this visit:&#xD;
&#xD;
             -  Subjective outcomes&#xD;
&#xD;
             -  Clinical Evaluation&#xD;
&#xD;
             -  Quadriceps strength testing&#xD;
&#xD;
             -  Concomitant medications&#xD;
&#xD;
             -  Adverse Events&#xD;
&#xD;
        -  3 months following injection: Patients will return at 12 weeks (approx 91±7 days)&#xD;
           following injection. The following outcomes will be recorded during this visit:&#xD;
&#xD;
             -  Subjective outcomes&#xD;
&#xD;
             -  Clinical Evaluation&#xD;
&#xD;
             -  Quadriceps strength testing&#xD;
&#xD;
             -  Concomitant medications&#xD;
&#xD;
             -  Adverse Events&#xD;
&#xD;
        -  6 months following injection: Patients will return at 26 weeks (approx 182±14 days)&#xD;
           following injection. The following outcomes will be recorded during this visit:&#xD;
&#xD;
             -  Subjective outcomes&#xD;
&#xD;
             -  Clinical Evaluation&#xD;
&#xD;
             -  Quadriceps strength testing&#xD;
&#xD;
             -  Concomitant medications&#xD;
&#xD;
             -  Adverse Events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Pain During a Single Leg Squat</measure>
    <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
    <description>Participants will be asked to rate their worst knee pain on a visual analog scale during a deep single leg squat. The scale ranges from 0-10 where higher numbers indicate more pain. A score of 0 indicates no pain and a score of 10 indicates worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS: Patient Reported Knee Function</measure>
    <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
    <description>Patients will be asked to complete several validated questionnaires to assess their knee symptoms and daily function. The Knee Osteoarthritis Outcome Score (KOOS) was used as a cumulative score that included all sub-scales. The resultant score ranged from 0-100 where higher scores indicated better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps Muscle Function</measure>
    <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
    <description>Participants will contract their thigh muscle as hard as possible in order to measure their maximum strength. The outcome measure is maximum strength expressed in Newton-meters/kilogram. This outcome ranges from 0 indicating no strength to infinity where higher scores indicate stronger muscles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Chondromalacia Patella</condition>
  <condition>Patellofemoral Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Synvisc-One™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synvisc-One™</intervention_name>
    <description>A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
    <arm_group_label>Synvisc-One™</arm_group_label>
    <other_name>Hyaluronan</other_name>
    <other_name>Hyaluronic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>A single needle stick without arthrocentesis or injection.</description>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at time of randomization: 18-45 years&#xD;
&#xD;
          -  Clinical diagnosis of anterior knee pain&#xD;
&#xD;
          -  X-ray showing no fracture or osteoarthritis&#xD;
&#xD;
          -  &gt;4 out of 10 on a visual analog scale and/or Knee &amp; Osteoarthritis Outcome Score&#xD;
             (KOOS) &lt;7&#xD;
&#xD;
          -  Persistent anterior knee pain lasting at least 3 months prior to screening&#xD;
&#xD;
          -  Failed previous physical therapy intervention&#xD;
&#xD;
          -  Pain/crepitus with patellar grind&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of knee/ patellofemoral joint effusion&#xD;
&#xD;
          -  Patellar tendonitis&#xD;
&#xD;
          -  Patellofemoral joint space narrowing as noted on Merchant/sunrise x-ray&#xD;
&#xD;
          -  Diagnosis of tibiofemoral osteoarthritis&#xD;
&#xD;
          -  Cruciate/ collateral knee ligament instability&#xD;
&#xD;
          -  Patellofemoral joint instability&#xD;
&#xD;
          -  Significant patellar or tibiofemoral mal-alignment&#xD;
&#xD;
          -  Suspected meniscus injury&#xD;
&#xD;
          -  Any clinical indication for arthroscopic surgery&#xD;
&#xD;
          -  Significant patellar mal-tracking as noted on merchant view x-ray&#xD;
&#xD;
          -  Currently enrolled in another experimental clinical trial&#xD;
&#xD;
          -  Patellofemoral joint injection within the past 3 months&#xD;
&#xD;
          -  Known or suspected psychological disorder&#xD;
&#xD;
          -  Known allergy to avian products&#xD;
&#xD;
          -  Oral steroid medications&#xD;
&#xD;
          -  Intra-articular (knee joint) steroids in the past 6 months&#xD;
&#xD;
          -  Any prior use of viscosupplements&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Body mass index &gt; 40&#xD;
&#xD;
          -  Prior surgery in the knees (excludes debridement only procedures)&#xD;
&#xD;
          -  Clinical evidence of hip disease&#xD;
&#xD;
          -  Any form of inflammatory arthritis ( e.g. RA, gout, pseudogout, lupus, etc)&#xD;
&#xD;
          -  Significant co-morbid conditions as determined by the investigator&#xD;
&#xD;
          -  Willing to refrain from chiropractic treatment or acupuncture during the study&#xD;
&#xD;
          -  Any other intra-articular knee joint injection during the study&#xD;
&#xD;
          -  Kellgren Lawrence grade osteoarthritis of II, III or IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Hart, PhD, ATC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Diduch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <results_first_submitted>July 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Joseph Hart</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Patellofemoral Chondromalacia</keyword>
  <keyword>Anterior Knee Pain</keyword>
  <keyword>Patellofemoral Pain Syndrome</keyword>
  <keyword>Synvisc-One</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Patellofemoral Pain Syndrome</mesh_term>
    <mesh_term>Cartilage Diseases</mesh_term>
    <mesh_term>Chondromalacia Patellae</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synvisc-One™</title>
          <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
        </group>
        <group group_id="P2">
          <title>Sham Treatment</title>
          <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synvisc-One™</title>
          <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
        </group>
        <group group_id="B2">
          <title>Sham Treatment</title>
          <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="7"/>
                    <measurement group_id="B2" value="28.1" spread="8.4"/>
                    <measurement group_id="B3" value="27.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Knee Pain During a Single Leg Squat</title>
        <description>Participants will be asked to rate their worst knee pain on a visual analog scale during a deep single leg squat. The scale ranges from 0-10 where higher numbers indicate more pain. A score of 0 indicates no pain and a score of 10 indicates worst possible pain.</description>
        <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
        <population>107 patients were screened, 86 were randomized (45 Synvisc one injection, 41 sham), 6 were lost to follow up leaving 42 in the Synvisc one and 38 in the sham group that completed the follow up visit and were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Synvisc-One™</title>
            <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Pain During a Single Leg Squat</title>
          <description>Participants will be asked to rate their worst knee pain on a visual analog scale during a deep single leg squat. The scale ranges from 0-10 where higher numbers indicate more pain. A score of 0 indicates no pain and a score of 10 indicates worst possible pain.</description>
          <population>107 patients were screened, 86 were randomized (45 Synvisc one injection, 41 sham), 6 were lost to follow up leaving 42 in the Synvisc one and 38 in the sham group that completed the follow up visit and were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.9"/>
                    <measurement group_id="O2" value="5.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.5"/>
                    <measurement group_id="O2" value="3.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.5"/>
                    <measurement group_id="O2" value="2.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.4"/>
                    <measurement group_id="O2" value="2.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>KOOS: Patient Reported Knee Function</title>
        <description>Patients will be asked to complete several validated questionnaires to assess their knee symptoms and daily function. The Knee Osteoarthritis Outcome Score (KOOS) was used as a cumulative score that included all sub-scales. The resultant score ranged from 0-100 where higher scores indicated better function.</description>
        <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
        <population>107 patients were screened, 86 were randomized (45 Synvisc one injection, 41 sham), 6 were lost to follow up leaving 42 in the Synvisc one and 38 in the sham group that completed the follow up visit and were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Synvisc-One™</title>
            <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS: Patient Reported Knee Function</title>
          <description>Patients will be asked to complete several validated questionnaires to assess their knee symptoms and daily function. The Knee Osteoarthritis Outcome Score (KOOS) was used as a cumulative score that included all sub-scales. The resultant score ranged from 0-100 where higher scores indicated better function.</description>
          <population>107 patients were screened, 86 were randomized (45 Synvisc one injection, 41 sham), 6 were lost to follow up leaving 42 in the Synvisc one and 38 in the sham group that completed the follow up visit and were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" spread="11.5"/>
                    <measurement group_id="O2" value="64.9" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="14.8"/>
                    <measurement group_id="O2" value="79.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="16.6"/>
                    <measurement group_id="O2" value="79.9" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="15.2"/>
                    <measurement group_id="O2" value="82.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quadriceps Muscle Function</title>
        <description>Participants will contract their thigh muscle as hard as possible in order to measure their maximum strength. The outcome measure is maximum strength expressed in Newton-meters/kilogram. This outcome ranges from 0 indicating no strength to infinity where higher scores indicate stronger muscles.</description>
        <time_frame>Baseline, 1 month, 3 month and 6 month</time_frame>
        <population>The data reported below are from 45 patients randomized to Synvisc one and 41 patients randomized to sham.</population>
        <group_list>
          <group group_id="O1">
            <title>Synvisc-One™</title>
            <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Quadriceps Muscle Function</title>
          <description>Participants will contract their thigh muscle as hard as possible in order to measure their maximum strength. The outcome measure is maximum strength expressed in Newton-meters/kilogram. This outcome ranges from 0 indicating no strength to infinity where higher scores indicate stronger muscles.</description>
          <population>The data reported below are from 45 patients randomized to Synvisc one and 41 patients randomized to sham.</population>
          <units>Newton-meters/kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread=".88"/>
                    <measurement group_id="O2" value="1.84" spread=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread=".8"/>
                    <measurement group_id="O2" value="1.84" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread=".82"/>
                    <measurement group_id="O2" value="1.68" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread=".74"/>
                    <measurement group_id="O2" value="1.59" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Synvisc-One™</title>
          <description>Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.&#xD;
Synvisc-One™: A single 6cc injection of Synvisc-One™ will be utilized in this study.</description>
        </group>
        <group group_id="E2">
          <title>Sham Treatment</title>
          <description>Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.&#xD;
Sham Treatment: A single needle stick without arthrocentesis or injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain and/or stiffness</sub_title>
                <description>Self reported knee pain and / or knee stiffness</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Knee Effusion with or without pain</sub_title>
                <description>Knee swelling noted on exam during research visits with or without self reported knee pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joe Hart</name_or_title>
      <organization>University of Virginia, Kinesiology</organization>
      <phone>4349246187</phone>
      <email>jmh3zf@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

